FCGR1A and acute myeloid leukemia: Finally, when comparing the efficacy of AFM28 to that of the Fc-enhanced anti‐CD123 IgG1, there was a significant trend for superior AML blast reduction by AFM28 in comparison to the Fc-enhanced anti‐CD123 IgG1, in particular towards leukemic blasts with high CD64 expression (Fig. 2E–H and Supplementary Fig. 2E).